Slides
Page 1
Lilly 1876 150 2026 YEARS OF MEDICINE
Page 2
Q2 2026 Earnings Call Eli Lilly and Company
Page 3
2026 Q2 Earnings 3 Agenda Introduction and Key Events David Ricks, Chair and Chief Executive Officer Q2 2026 Financial Results Lucas Montarce, Chief Financial Officer R&D Update Dan Skovronsky, M.D., Ph.D., Chief Scientific and Product Officer Question & Answer Session
Page 4
2026 Q2 Earnings Not for promotional use 4 Safe Harbor Provision and Other Information This presentation contains forward - looking statements that are based on management's current expectations, but actual results ma y differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; litigation and investigations; business development transactions; tra de and economic conditions; the implementation of our voluntary agreement with the U.S. government related to drug pricing and access; and changes in law s a nd regulations, including healthcare reform. For additional information about the factors that affect the company's business, please see the company's latest Form 10 - K and subsequent Forms 10 - Q and 8 - K filed with the Securities and Exchange Commission. Certain financial information in this prese ntation is presented on a non - GAAP basis. Investors should refer to the reconciliations included in this presentation and should consider the company's no n - GAAP measures in addition to, not as a substitute for or superior to, measures prepared in accordance with GAAP. These materials are not intended to pr omo te the products referenced herein or otherwise influence healthcare prescribing decisions. The safety and efficacy of the agents under investigation hav e n ot been established. There is no guarantee that the agents will receive regulatory approval or become commercially available for the uses being investigated. Numbers in this presentation may not add due to rounding. Market positions represent estimates for performance based on indicated data sources. These figures do not reflect Lilly's sh are of any relevant antitrust market and do not include the full set of therapeutic or other alternatives reasonably available to patien ts and prescribers. The company undertakes no duty to update forward - looking statements except as required by applicable law.
Page 5
2026 Q2 Earnings Not for promotional use 5 Q2 2026 Progress on Strategic Deliverables • Opened Lebanon Advanced Therapies genetic medicine manufacturing facility • Produced first commercial material at Limerick manufacturing facility • Announced acquisition of AtaiBeckley • Completed acquisitions of Curevo, LimmaTech Biologics, and Vaccine Company • 121% Key Product revenue growth in Oncology, Immunology and Neuroscience • Ebglyss approved for once every eight weeks maintenance dosing • Jaypirca approved in line - agnostic CLL in EU • Incretin revenue grew 67% driven by market growth and increased global share • Expanded access to obesity medicines through Medicare GLP - 1 Bridge program • Positive data in TRIUMPH - 1, TRIUMPH - 2 and TRIUMPH - 3 for retatrutide • Positive CHMP opinion for Onswik (insulin efsitora alfa) $23.0B↑ 48% $8.38↑ 33% + 76 % Q2 WORLDWIDE REVENUE KEY PRODUCT REVENUE GROWTH NON-GAAP EPS Growth rates reflect change vs Q2 2025 The Company currently defines Key Products as Ebglyss , Foundayo (added Q2 2026), Inluriyo , Jaypirca , Kisunla , Mounjaro, Omvoh , and Zepbound Incretins include Foundayo, Mounjaro, Zepbound and Trulicity Invest to Drive Future Growth Expand Presence in Other Therapeutic Areas Broaden Impact on Cardiometabolic Health
Page 6
2026 Q2 Earnings Not for promotional use 6 Medicare GLP - 1 Bridge Progress ~20 million Potential patients eligible under the Medicare Bridge Program $50 / month Out of pocket cost for Medicare beneficiaries ~60 - 70% Patients are new incretin starts ~ 35% Increase in U.S. covered lives for Lilly obesity medicines
Page 7
2026 Q2 Earnings GAAP Reported Adjustments Non - GAAP Adjusted YoY Non - GAAP Adjusted Change Total revenue $22,974 $ - $22,974 48% Gross margin 85.8% 0.5pp 86.3% +1.3pp Total operating expense $10,728 $(703) $10,025 61% Operating income $8,978 $828 $9,806 40% Other income (expense) $269 $(445) $(176) - 7% Effective tax rate 23.3% - 1.1pp 22.2% +5.7pp Net income $7,095 $398 $7,493 32% EPS $7.94 $0.44 $8.38 33% Acquired IPR&D Charge per share 1 $3.03 $ - $3.03 NM Performance Margin 2 51.2% 54.8% +8.9pp 1 Acquired IPR&D (in - process research and development) charge of $2.8 billion (pre - tax). Not for promotional use 7 2 The Company defines Performance Margin as gross margin less research and development, marketing, selling and administrative, and ass et impairment, restructuring and other special charges divided by revenue Note: The Non - GAAP Performance Margin excludes the amortization of intangible assets. The applicable impact of amortization of i ntangible assets can be found in the reconciliation tables on slide 23. Dollars in millions; except per share data Q2 2026 Key Income Statement Measures (unaudited)
Page 8
2026 Q2 Earnings Amount Price FX Rate Volume Total CER U.S. $14,413 (3)% - 37% 33% 33% Europe $4,115 7% 4% 49% 60% 55% Japan $628 (9)% (9)% 39% 21% 30% China 1 $941 NM 9% NM 102% 93% Rest of world $2,877 (4)% 7% 141% 143% 136% Total Revenue $22,974 (13)% 1% 60% 48% 46% Dollars in millions. Numbers may not add due to rounding. CER= price change + volume change; NM = not meaningful 1 China price and volume driven by inclusion of Mounjaro on National Reimbursement Drug List for Type 2 Diabetes, with lower pr ice and higher volume vs. Q2 2025 and YTD 2025 Dollars in m illions Not for promotional use 8 Price/Rate/Volume Effect on Revenue Q2 2026 Amount Price FX Rate Volume Total CER U.S. $26,532 (5)% - 42% 37% 37% Europe $7,760 6% 10% 41% 56% 46% Japan $1,199 (4)% (5)% 40% 30% 35% China 1 $1,635 NM 5% NM 78% 73% Rest of world $5,648 (4)% 8% 155% 159% 151% Total Revenue $42,773 (13)% 2% 62% 51% 49% YTD 2026
Page 9
2026 Q2 Earnings $0 $2,000 $4,000 $6,000 $8,000 $10,000 $12,000 $14,000 $16,000 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2023 2024 2025 2026 Millions Not for promotional use 9 Cardiometabolic Health Mounjaro Q2 2026 sales of $9.9B, +91% vs Q2 2025 Zepbound Q2 2026 sales of $4.9B, +46% vs. Q2 2025 Foundayo Q2 2026 sales of $98M Immunology Ebglyss Q2 2026 sales of $201M, +131% vs. Q2 2025 Oncology Jaypirca Q2 2026 sales of $192M, +56% vs. Q2 2025 Inluriyo Q2 2026 sales of $75M Neuroscience Kisunla Q2 2026 sales of $167M Q2 2026 Update on Key Products $15.7B Key Product revenue, accelerating to 76% growth year over year The Company currently defines Key Products as Ebglyss , Foundayo (added Q2 2026), Inluriyo (added Q4 2025), Jaypirca , Kisunla , Mounjaro, Omvoh , and Zepbound. +121% Key Product revenue growth in Immunology, Oncology & Neuroscience
Page 10
2026 Q2 Earnings 0 300 600 900 1,200 1,500 1,800 2,100 2,400 2,700 Source: IQVIA weekly NPA total prescriptions, weekly data 6/26/2026 Rolling 4 week SOM. Incretin analogs market includes injectable GLP - 1s, oral GLP - 1s and GLP - 1/GIP dual agonists Not for promotional use 10 Total Prescriptions 4 Week Rolling Average (thousands) U.S. Incretin Analogs Market +3 1 % Q2 2026 U.S. market growth 60.9% Lilly share of market Lilly SOM 60.9 % Total Prescriptions Novo SOM 38.8%
Page 11
2026 Q2 Earnings $0.0 $0.5 $1.0 $1.5 $2.0 $2.5 $3.0 Gross Revenue 3 Month Rolling Average (billions) Not for promotional use 11 International Incretin Analogs Market +74% Q2 2026 market growth 54.9% Lilly share of market Growth rate: April /May 2026 vs. April/May 2025 Data source: IQVIA GMI Agent AI, MIDAS Monthly accessed 7/29/2026 Sales in US dollars at the exchange rate in effect at the time of sale based on wholesaler purchase price and manufacturer’s selling price Market basket: Bydureon /Byetta, Foundayo, Lyxumia , Mounjaro, Ozempic, Rybelsus, Saxenda, Trulicity, Wegovy, Victoza, Zepbound Geography: Worldwide excluding USA and Puerto Rico Lilly SOM 54.9% Total Revenue Novo SOM 45.1%
Page 12
2026 Q2 Earnings Not for promotional use 12 Foundayo Launch and Clinical Progress 2026 Launched in all major markets Mexico and Saudi Arabia approvals only; product launch later this year US Sampling and HCP engagement DTC expansion launched in June Medicare GLP - 1 Bridge effective July Type 2 Diabetes Regulatory Action International Expected Phase 3 Readouts 2027+ Stress urinary incontinence Knee osteoarthritis pain Hypertension Peripheral artery disease Cardiovascular outcomes Type 2 Diabetes (ACHIEVE - 4) Obstructive sleep apnea UAE (obesity) Mexico (obesity & T2D) Saudi Arabia (obesity) Select additional markets Continued uptake and market expansion Significant global multi - indication cardiometabolic opportunity building into 2027 and beyond
Page 13
2026 Q2 Earnings R&D 2 Capital Investments Business Development 1 Share Repurchase Dividend 1 Includes development milestones, closed acquisitions and cash outflows associated with equity investments 2 After tax Not for promotional use 13 YTD 2026 Capital Allocation $ in b illions GROWTH RETURN $3.1 $4.0 $5.2 $6.0 $15.3
Page 14
2026 Q2 Earnings Not for promotional use 14 Prior Updated Comments Revenue 1 $82.0 – $85.0 billion $85.0 – $87.0 billion Strong underlying business performance; increased midpoint of the range by $2.5B reflecting 32% year over year growth Performance Margin 2 47.0% – 48.5% 49.0% – 50.5% Increased by 2.0pp to reflect updated revenue expectations Tax Rate Approximately 18 - 19% Unchanged Earnings Per Share 3 $35.50 – $37.00 $35.50 – $36.50 Increased $2.78 at midpoint to reflect updated revenue expectations before updating guidance for $3.03 impact of Q2 2026 acquired IPR&D charges 2026 Guidance (Non - GAAP) 1 GAAP measure 2 The Company define s Non - GAAP Performance Margin as gross margin less research and development and marketing, selling, and administrative expenses d ivided by revenue. 3 2026 assumes shares outstanding of approximately 894 million Note: See slide 23 for additional Non - GAAP information. FX assumptions of 1.14 (Euro), 153 (Yen) and 7.1 (Yuan)
Page 15
2026 Q2 Earnings Not for promotional use 15 Retatrutide Showed Powerful Efficacy in TRIUMPH Trials Change from Baseline Weight 1 TRIUMPH - 2 vs. placebo Obesity with T2D 80 weeks 106.4 kg TRIUMPH - 1 vs. placebo Obesity 80 weeks 112.7 kg TRIUMPH - 3 vs. placebo Class II - III Obesity with CVD ± T2D 80 weeks 111.4 kg TRIUMPH - 4 vs. placebo Obesity with OA 68 weeks 112.7 kg Baseline Body Weight: - 2.2% - 19.0% - 25.9% - 28.3% PBO 4 mg 9 mg 12 mg - 4.0% - 12.7% - 19.1% - 20.8% PBO 4 mg 9 mg 12 mg - 3.2% - 21.6% - 22.6% PBO 9 mg 12 mg - 2.1% - 26.4% - 28.7% PBO 9 mg 12 mg First - of - its - kind medicine delivered clinically meaningful weight loss, with most common adverse events generally consistent wit h other incretins T2D = type 2 diabetes; CVD = cardiovascular disease; OA = osteoarthritis of the knee; PBO = placebo 1 Efficacy estimand
Page 16
2026 Q2 Earnings 0.0 0.5 1.0 1.5 Not for promotional use 16 Jaypirca PFS in R/R CLL Using a Time - Limited Regimen PFS = progression free survival; R/R = relapsed / refractory; CLL = chronic lymphocytic leukemia; cBTKi = covalent Bruton tyrosine kinase inhibitor; VR = venetoclax + rituximab; PD = Progressive Disease 1 IRC - assessed progression free survival data The overall safety profile of fixed - duration Jaypirca + VR was generally similar to VR alone BRUIN CLL - 322 Select Hazard Ratios (95% CI) 1 Disease Progression on One Prior cBTKi 1 reduction in risk of progression or death vs VR 68% Favors Jaypirca + VR Favors VR Overall Prior cBTKi Treated Prior cBTKi Discontinued due to PD 0.51 (0.35 – 0.74) 0.44 (0.29 – 0.67) 0.32 (0.14 – 0.73) One Prior cBTKi Discontinued due to PD 0.55 (0.40 – 0.75) Jaypirca + VR VR
Page 17
2026 Q2 Earnings Not for promotional use 17 Significant R&D Progress through M&A CMH ONCOLOGY NEUROSCIENCE IMMUNOLOGY INFECTIOUS DISEASE Note: AtaiBeckley transaction expected to close in Q3 2026
Page 18
2026 Q2 Earnings BRENIPATIDE IBS - C BRENIPATIDE IBS - D TIRZEPATIDE Higher Doses ZOTEMTEGRAST + MIRIKIZUMAB UC ZOTEMTEGRAST Crohn’s Disease BRENIPATIDE Schizophrenia BRENIPATIDE Tobacco Use Disorder ELTREKIBART Ulcerative Colitis BRENIPATIDE Asthma BRENIPATIDE Bipolar Disorder BRENIPATIDE Opioid Use Disorder CLEMINOREXTON Central Hypersomnias FXR AGONIST + MIRIKIZUMAB CD XCL1/2 Ab Vitiligo ZOTEMTEGRAST Ulcerative Colitis AMEZOSVATEIN Shingles CLAZAKIZUMAB Inflammatory Disorders SIMEPDEKINRA Psoriasis SOLBINSIRAN Severe Hypertriglyceridemia TURIGROBART Pain NLRP3 INH II (VTX2735) Recurrent Pericarditis OTOF GENE THERAPY Hearing Loss SILMORETGENE PARVEC (AIPL1 - GT) AIPL1 - IRD NAV1.8 INH (SM) Pain NISOTIROSTIDE Diabetes NLRP3 INH (VTX3232) Inflammatory Disorders MACUPATIDE Obesity MEVIDALEN Symptomatic AD NAPERIGLIPRON Obesity GBA1 GENE THERAPY Parkinson’s Disease GIPR AGONIST LA CINV GS INSULIN RECEPTOR AGONIST Diabetes AT2R ANTAGONIST Pain BIMAGRUMAB Obesity ELTREKIBART Hidradenitis Suppurativa Not for promotional use 18 TIRZEPATIDE Type 1 Diabetes SELPERCATINIB Adjuvant RET+ NSCLC SOFETABART MIPITECAN PSOC TIRZEPATIDE Morbidity and Mortality in Obesity TIRZEPATIDE MASLD RETATRUTIDE Chronic Low Back Pain RETATRUTIDE CV / Renal Outcomes RETATRUTIDE Diabetes RETATRUTIDE MASLD ORFORGLIPRON Osteoarthritis Pain ORFORGLIPRON Peripheral Artery Disease ORFORGLIPRON Stress Urinary Incontinence PIRTOBRUTINIB R/R MCL Monotherapy OLOMORASIB Adj KRAS G12C+ NSCLC (unresected) ORFORGLIPRON Cardiovascular Outcomes ORFORGLIPRON Hypertension ORFORGLIPRON Obstructive Sleep Apnea MIRIKIZUMAB + TIRZEPATIDE CD MIRIKIZUMAB + TIRZEPATIDE UC OLOMORASIB 1L KRAS G12C+ NSCLC (PD - L1 high) OLOMORASIB Adj KRAS G12C+ NSCLC (resected) IXEKIZUMAB + TIRZEPATIDE PsA IXEKIZUMAB + TIRZEPATIDE Psoriasis LEBRIKIZUMAB AR (perennial allergens) LEBRIKIZUMAB CRSwNP ELORALINTIDE INCRETIN ADD - ON Obesity ELORALINTIDE Obstructive Sleep Apnea ELORALINTIDE Osteoarthritis Pain IMLUNESTRANT Adjuvant Breast Cancer SOFETABART MIPITECAN PROC BARICITINIB Type 1 Diabetes BRENIPATIDE Major Depressive Disorder DONANEMAB Cognitively Unimpaired AD MUVALAPLIN ASCVD OLOMORASIB 1L KRAS G12C+ NSCLC (All PD - L1) REMTERNETUG Cognitively Unimpaired / MCI due to AD RETATRUTIDE Obesity, OA, OSA BRENIPATIDE Alcohol Use Disorder ELORALINTIDE Obesity IXO - VEC wet Age - Related Macular Degeneration LEPODISIRAN ASCVD PIRTOBRUTINIB R/R CLL Combination TIRZEPATIDE Cardiovascular Outcomes ORFORGLIPRON Diabetes INSULIN EFSITORA ALFA Diabetes Lilly Select Pipeline As of August 3, 2026 PHASE 2 PHASE 3 REG REVIEW NME NILEX / Other UPDATES SINCE April 28, 2026 REMOVAL ADDITION OR MILESTONE ACHIEVED GBA1 GENE THERAPY Gaucher Disease Type 1 PIRTOBRUTINIB 1L CLL Monotherapy APPROVED
Page 19
2026 Q2 Earnings Not for promotional use 19 Potential Key Events 2026 New since last update Eloralintide for obesity or overweight Eloralintide incretin add - on for obesity or overweight Eloralintide for OA knee pain and obesity or overweight Eloralintide for OSA and obesity or overweight Orforglipron for peripheral artery disease Vepugratinib for 1L metastatic urothelial cancer Tersolisib for advanced breast cancer Sofetabart Mipitecan for platinum - resistant ovarian cancer Sofetabart Mipitecan for platinum - sensitive ovarian cancer Brenipatide for major depressive disorder Baricitinib for type 1 diabetes Phase 3 Initiations Ixekizumab and tirzepatide for psoriatic arthritis and obesity or overweight Ixekizumab and tirzepatide for psoriasis and obesity or overweight Orforglipron for type 2 diabetes [ACHIEVE - 4] Orforglipron for obstructive sleep apnea Retatrutide for obesity or overweight [TRIUMPH 1 /2 /3 ] Retatrutide for type 2 diabetes [TRANSCEND - T2D 1 /2/3] Lebrikizumab for pediatric atopic dermatitis Pirtobrutinib for R/R CLL combination [BRUIN CLL - 322] Phase 3 Data Disclosures Orforglipron for type 2 diabetes [US / EU /J ] Orforglipron for obstructive sleep apnea and obesity or overweight Retatrutide for overweight or obesity (now expected 2027) Retatrutide for OSA and obesity or overweight (now expected 2027) Retatrutide for OA pain of the knee and obesity or overweight (now expected 2027) Pirtobrutinib for R/R CLL combination Selpercatinib for adjuvant RET fusion - positive non - small cell lung cancer Lebrikizumab for pediatric atopic dermatitis Regulatory Submissions Regulatory Actions Zepbound KwikPen [US] Tirzepatide for cardiovascular outcomes Orforglipron for overweight or obesity [US] Orforglipron for type 2 diabetes Insulin efsitora alfa for type 2 diabetes Pirtobrutinib for 1L CLL [EU] Lebrikizumab maintenance dosing once every 8 weeks
Page 20
2026 Q2 Earnings Not for promotional use 20 Q2 2026 Summary Invest to Drive Future Growth Expand Presence in Other Therapeutic Areas Broaden Impact on Cardiometabolic Health ↑ 48% $8.38 3 Revenue growth Non - GAAP EPS Positive Phase 3 Retatrutide Trials $85.0B - $87.0B $35.50 - $36.50 Increased full year revenue guidance Increased non - GAAP EPS guidance 4 Acquisitions announced 2 Manufacturing site milestones 2 Label Expansions
Page 21
2026 Q2 Earnings Not for promotional use 21 Supplemental Slides 2026 Q2 Earnings
Page 22
2026 Q2 Earnings Not for promotional use 22 2026 Income Statement – Reported * Includes research and development expense; marketing, selling and administrative; acquired in - process research and development charges; and asset impairment, restructuring and other special charges (as applicable) Q2 2026 Change Total revenue $22,974 48% Gross margin 85.8% +1.5pp Total operating expense* $10,728 72% Operating income $8,978 31% Operating margin 39.1% - 5.0pp Other income (expense) $269 NM Effective tax rate 23.3% +6.8pp Net income $7,095 25% EPS $7.94 26% Dollars in millions; except per share data
Page 23
2026 Q2 Earnings Not for promotional use 23 Q2 2026 Q2 2025 % Change Earnings per share (reported) $7.94 $6.29 26% Asset impairment, restructuring and other special charges 0.72 -- NM Amortization of intangible assets 0.11 0.11 (1)% Net losses (gains) on investments in equity securities (0.39) (0.09) NM Earnings per share (Non - GAAP) $8.38 $6.31 33% Acquired IPR&D $3.03 $0.14 NM Numbers may not add due to rounding; see slide 24 for more details on these adjustments; NM = not meaningful EPS Reconciliation
Page 24
2026 Q2 Earnings Not for promotional use 24 Q2 Non - GAAP Adjustments Q2 2026 non - GAAP information has been adjusted to exclude: • Asset impairment, restructuring and other special charges, driven primarily by Kelonia and Centessa acquisition and integration costs, totaling $703 million (pre - tax), or $0.72 per share (after - tax) • Amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling $125 million (pre - tax), or $0.11 per share (after - tax) • Net gains on investments in equity securities totaling $445 million (pre - tax), or ($0.39) per share (after - tax) Q2 2025 non - GAAP information has been adjusted to exclude: • Amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling $122 million (pre - tax), or $0.11 per share (after - tax) • Net gains on investments in equity securities totaling $99 million (pre - tax), or ($0.09) per share (after - tax)
Page 25
2026 Q2 Earnings Not for promotional use 25 Q2 2026 Mounjaro Sales Increased $4.7B 0 200 400 600 800 1,000 1,200 1,400 1,600 0% 10% 20% 30% 40% 50% 60% Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 13 Wk RA TRX Market Size 13 wk RA TRx SOM U.S. TRX SOM and Market Volume Source: IQVIA NPA TRx 3MMA, weekly data June 26, 2026; RA = rolling average TRx data is representative of the Incretin Analogs - type 2 diabetes market Mounjaro U.S. sales were $4.8 billion International sales were $5.2 billion Market $ in billions $3.8 $5.2 $6.5 $7.4 $8.7 $9.9 Q1 Q2 Q3 Q4 2025 2026
Page 26
2026 Q2 Earnings Not for promotional use 26 Q2 2026 Zepbound Sales Increased $1.5B 0 200 400 600 800 1,000 1,200 1,400 0% 10% 20% 30% 40% 50% 60% 70% Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 13 Wk RA TRX Market Size 13 wk RA TRx SOM $2.3 $3.4 $3.6 $4.3 $4.2 $4.9 Q1 Q2 Q3 Q4 2025 2026 Source: IQVIA NPA TRx 3MMA, weekly data June 26, 2026; RA = rolling average TRx data is representative of the branded incretin analogs – OMM market Zepbound Market 1 Tirzepatide is marketed for obesity under the brand name Zepbound in Canada, Japan, and the United States . International sales were $55 million in Q2 2026 U.S. sales were $4.9 billion 1 $ in billions U.S. TRX SOM and Market Volume
Page 27
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT031559971 Breast Cancer Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) 3 5637 Invasive Disease-Free Survival Mar 2020 May 2029 NCT05169567 Breast Cancer Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMONARCH) 3 368 Progression-Free Survival (PFS) Feb 2024 Dec 2027 Not for promotional use 27 1 Also lists NSABP Foundation Inc * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Select Trials – Abemaciclib
Page 28
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT07222332 Type 1 Diabetes A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) 3 300 Change from Baseline in C-peptide Area Under the Curve (AUC) Jul 2028 Jul 2028 NCT07222137 Type 1 Diabetes A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (BARICADE-DELAY) 3 150 Time from Baseline to Diagnosis of Stage 3 Type 1 Diabetes Jul 2031 Jul 2031 Not for promotional use 28 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Select Trials – Baricitinib
Page 29
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT07412756 Major Depressive Disorder A Study of Brenipatide in Adult Participants With Major Depressive Disorder (RENEW-MDD-1) 3 1000 Time to Relapse as Measured by Number of Days from Randomization to Date Participant Meets Any Relapse Criterion of MDD Feb 2028 Feb 2028 NCT07219966 Alcohol Use Disorder A Study of Brenipatide in Participants With Moderate- to-Severe Alcohol Use Disorder (RENEW-ALC-1) 3 1100 Change in Drinking Patterns in Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method (TLFB) Apr 2028 Apr 2028 NCT07219953 Alcohol Use Disorder A Study of Brenipatide in Participants With Alcohol Use Disorder (RENEW-ALC-2) 3 1100 Change in Drinking Patterns in Alcohol Use Disorder (AUD) as Assessed by the Timeline Followback Method (TLFB) Apr 2028 Apr 2028 NCT07420283 Opioid Use Disorder A Study of Brenipatide in Participants With Opioid Use Disorder (RENEW-Op-1) 2 465 Percentage of weeks abstinence from opioid use defined by both negative urine drug screen (UDS) and no self-report of opioid use based on timeline follow back (TLFB) Achievement of >=80% weeks of abstinence from opioid use defined by both negative UDS and no self-report of opioid use based on TLFB Mar 2028 Mar 2028 NCT07286175 Bipolar Disorder A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1) 2 400 Time to Relapse Defined as Days from Randomization to the Date on Which the Participant Meets Any Relapse Criterion Nov 2027 Nov 2027 NCT07223840 Tobacco Use Disorder A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse (RENEW-Smk-1) 2 222 Percentage of Participants that Achieve Carbon Monoxide (CO)-Confirmed Continuous Abstinence from Cigarette Smoking with Allowed Slips Feb 2027 Feb 2027 NCT07410507 Schizophrenia A Study of Brenipatide in Adult Participants With Schizophrenia (RENEW-Scz-1) 2 450 Percent Change from Baseline in Body Weight in Participants with a Baseline Body Mass Index ≥25.0 Kilograms per Meter Squared (kg/m²) Nov 2027 Nov 2027 Not for promotional use 29 Source: clinicaltrials.gov, July 30, 2026 Select Trials – Brenipatide * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes
Page 30
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT07219173 Asthma A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma (RENEW-Asthma) 2 531 Annualized Asthma Exacerbation Rate Over 52 Weeks of Treatment Apr 2028 Jun 2028 NCT07545759 Irritable Bowel Syndrome / Diarrhea A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D) (RENEW-IBS- D) 2 531 Percentage of Participants Who Had a Daily Composite Response for at Least 50 Percent (%) of Days Sep 2027 Nov 2027 NCT07545772 Irritable Bowel Syndrome / Constipation A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) (RENEW- IBS-C) 2 342 Percentage of Participants with a Weekly Composite Clinical Response for at Least 50 Percent (%) of Weeks Jul 2027 Sep 2027 Not for promotional use 30 Source: clinicaltrials.gov, July 30, 2026 Select Trials – Brenipatide (cont.) * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes
Page 31
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT04437511 Alzheimer's Disease A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) 3 1736 Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population) Apr 2023 Nov 2028 NCT05026866 Alzheimer's Disease A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3) 3 2996 Time to Clinical Progression of Composite Endpoint as Measured by Clinical Dementia Rating (CDR) Nov 2027 Nov 2027 NCT05508789 Alzheimer's Disease A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) 3 1500 Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) May 2028 Jul 2028 NCT05738486 Alzheimer's Disease A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6) 3 1175 Percentage of Participants with Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E) May 2024 May 2027 NCT07571161 Alzheimer’s Disease Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease 3 140 Time to Clinical Progression as Measured by Clinical Dementia Rating-Global Score (CDR-GS) Apr 2030 Apr 2030 NCT07602582 Alzheimer Disease / Dementia / Plaque, Amyloid A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT). 3 550 Change from Baseline as Measured by Clinical Dementia Rating - Sum of Boxes (CDR-SB) Sep 2029 Sep 2029 NCT07589595 Cognitive Dysfunction / Lewy Body Disease / Synucleinopathi es / Amyloid A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline, at Least One Core Clinical Feature of Dementia With Lewy Bodies, and Confirmation of Alpha-Synuclein and Amyloid Co- pathology (TRAILBLAZER-ALZ 7) 2 350 Change from Baseline on Clinical Dementia Rating - Sum of Boxes (CDR-SB) Aug 2028 Aug 2028 Not for promotional use 31 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Select Trials – Donanemab
Page 32
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT07321886 Obesity / Overweight A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes (ENLIGHTEN-1) 3 1980 Percent Change from Baseline in Body Weight Mar 2028 Jul 2030 NCT07282600 Obesity / Overweight A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes (ENLIGHTEN-2) 3 1035 Percent Change from Baseline in Body Weight Jan 2028 Feb 2028 NCT07369011 Obstructive Sleep Apnea / Obesity A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ENLIGHTEN-3) 3 800 Percent Change from Baseline in Body Weight and Change from Baseline in Apnea-Hypopnea Index Mar 2028 Apr 2028 NCT07353931 Osteoarthritis / Overweight Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight (ENLIGHTEN-4) 3 900 Percent Change from Baseline in Body Weight and Change from Baseline in WOMAC Pain Subscale Score Mar 2028 May 2028 NCT07392190 Obesity / Overweight A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin (ENLIGHTEN-6) 3 900 Percent Change from Baseline in Body Weight Jun 2028 Jul 2028 NCT06603571 Obesity A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes 2 367 Percent Change from Baseline in Body Weight July 2026 Aug 2026 Not for promotional use 32 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Select Trials – Eloralintide
Page 33
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT04975308 Breast Neoplasms A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3) 3 874 Progression-Free Survival (PFS) Jun 2024 Aug 2027 NCT05514054 Breast Neoplasms A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4) 3 8000 Invasive Disease-Free Survival (iDFS) Oct 2027 Mar 2032 NCT07287098 Breast Neoplasms A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (preEMBER) 2 600 Percent Change from Baseline in Ki67 Jan 2029 Dec 2029 Not for promotional use 33 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Select Trials – Imlunestrant
Page 34
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT06588283 Plaque Psoriasis / Obesity Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight (TOGETHER-PsO) 3 281 Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and at Least 10% Weight Reduction Jan 2026 June 2026 NCT06588296 Psoriatic Arthritis / Obesity Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight (TOGETHER-PsA) 3 279 Percentage of Participants Who Simultaneously Achieved American College of Rheumatology (ACR) ACR50 and at Least a 10% Weight Reduction Nov 2025 Apr 2026 Not for promotional use 34 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Select Trials – Ixekizumab
Page 35
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT05559359 Atopic Dermatitis A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1) 3 377 Percentage of Participants With Investigator Global Assessment (IGA) Score of 0 or 1 at Week 16 and a Reduction ≥2 points from Baseline Jan 2026 Dec 2026 NCT05735483 Atopic Dermatitis A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2) 3 333 Percentage of Participants Discontinued From Study Treatment due to Adverse Events (AEs) Dec 2027 Apr 2029 NCT06339008 Perennial Allergic Rhinitis A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1) 3 450 Mean Change From Baseline (CFBL) in Total Nasal Symptom Score (TNSS) at week 16 Sep 2026 Oct 2028 NCT06338995 Chronic Rhinosinusitis With Nasal Polyps A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) 3 510 Mean Change From Baseline (CFBL) in Participant Reported Nasal Congestion Score (NCS) Severity May 2027 Mar 2028 NCT06280716 Atopic Dermatitis A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis (Advance-Asia) 3 301 Percentage of Participants Achieving Eczema Area and Severity Index (EASI-75) ≥75% Reduction in EASI Score for Mono Cohort Sep 2025 Aug 2026 NCT06921759 Atopic Hand and Foot Dermatitis A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis (ADtouch) 3 221 Percentage of Participants Achieving a Hand and Foot Investigator Global Assessment (HF-IGA) Score of 0 or 1 with ≥2-point Improvement from Baseline May 2026 Jul 2026 Not for promotional use 35 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Select Trials – Lebrikizumab
Page 36
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT06292013 Atherosclerotic Cardiovascular Disease1 A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) 3 17300 Time to First Occurrence of Any Component of the Major Adverse Cardiovascular Event (MACE)-4 Composite Endpoint Mar 2029 Mar 2029 NCT07613294 Atherosclerosis / Cardiovascular Diseases / Lipoprotein(a) A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk – ACCLAIM- CTA 3 252 Percent Change from Baseline in Noncalcified Plaque (NCP) Volume Apr 2029 Dec 2029 Not for promotional use 36 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Select Trials – Lepodisiran 1 Reduction of major adverse cardiovascular events (MACE) in patients with Atherosclerotic Cardiovascular Disease (ASCVD) and those at-risk for ASCVD
Page 37
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT03519945 Ulcerative Colitis A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) 3 1153 Percentage of Participants in Clinical Remission Mar 2026 Apr 2028 NCT04232553 Crohn's Disease A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2) 3 996 Percentage of Participants Achieving Endoscopic Response Nov 2024 Mar 2028 NCT05509777 Crohn's Disease A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease (AMAY) 3 90 Percentage of Participants with Clinical Response by Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12 and Endoscopic Response by Simple Endoscopic Score for CD (SES-CD) at Week 52 Dec 2027 Apr 2028 NCT06937099 Crohn's Disease / Obesity Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight (COMMIT- CD) 3 290 Percentage of Participants Who Simultaneously Achieve Clinical Remission by Crohn's Disease Activity Index (CDAI), Endoscopic Remission, and at least 10% Weight Reduction May 2028 May 2028 NCT06937086 Ulcerative Colitis / Obesity Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study (COMMIT-UC) 3 350 Percentage of Participants Who Simultaneously Achieve Clinical Remission and at Least 10% Weight Reduction Apr 2028 Apr 2028 NCT07483099 Crohn's Disease A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease 2 60 Percentage of Participants with Crohn's Disease who Achieve Endoscopic Response Jun 2027 Mar 2028 NCT07186101 Ulcerative Colitis LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: (TOPAZ-UC) 2 252 Percentage of participants who simultaneously achieve clinical remission and at least 10% weight reduction May 2027 Mar 2029 NCT06598943 Ulcerative Colitis A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis 2 143 Percentage of Participants Achieving Clinical Remission Dec 2027 Sep 2028 Not for promotional use 37 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Select Trials – Mirikizumab
Page 38
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT07157774 Atherosclerotic Cardiovascular Disease1 Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) (MOVE-Lp(a)) 3 10450 Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint Mar 2031 Mar 2031 Not for promotional use 38 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Select Trials – Muvalaplin 1 Reduction of major adverse cardiovascular events (MACE) in patients with Atherosclerotic Cardiovascular Disease (ASCVD) and those at-risk for ASCVD
Page 39
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT06119581 Carcinoma, Non-Small-Cell Lung A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01) 3 1264 Dose Optimization and Safety Lead-In Part B: Number of Participants with a TEAE Nov 2027 Jan 2031 NCT068905981 Carcinoma, Non-Small-Cell Lung Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02) 3 700 Part A: Disease-Free Survival (DFS) by Investigator Assessment May 2029 Feb 2032 Not for promotional use 39 Source: clinicaltrials.gov, July 30, 2026 Select Trials – Olomorasib 1 Also lists AstraZeneca * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes
Page 40
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT05869903 Obesity / Overweight A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight- Related Comorbidities (ATTAIN-1) 3 3127 Mean Percent Change from Baseline in Body Weight Jul 2025 Oct 2027 NCT06649045 Obstructive Sleep Apnea / Obesity A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ATTAIN-OSA) 3 600 Change from Baseline in Apnea-Hypopnea Index (AHI) Nov 2026 Jan 2027 NCT06672939 Obesity / Overweight A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities 3 150 Percent Change from Baseline in Body Mass Index (BMI) Dec 2027 Jan 2031 NCT06948422 Hypertension A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension) 3 974 Change from baseline in systolic blood pressure Sep 2027 Sep 2027 NCT07241390 Cardiovascular Disease / Chronic Kidney Disease A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) 3 7140 Time to First Occurrence of Composite Endpoint of Major Cardiovascular Events Aug 2031 Aug 2031 NCT07153471 Osteoarthritis A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee (ATTAIN-OA PAIN) 3 800 Change from Baseline in WOMAC Pain Subscale Score Apr 2028 May 2028 NCT07223593 Peripheral Artery Disease Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease (ATTAIN-PAD) 3 1205 Percent Change from Baseline in Maximum Walking Distance Jun 2028 Jun 2028 NCT07202884 Stress Urinary Incontinence / Obesity A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight (RESTRAIN-SUI) 3 1000 Change from Baseline in Incontinence Episode Frequence (IEF) Mar 2028 Mar 2028 Not for promotional use 40 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Select Trials – Orforglipron
Page 41
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT06972459 Obesity / Overweight A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight- Related Comorbidity 3 800 Percent Change from Baseline in Body Weight Aug 2027 Aug 2027 NCT06972472 Obesity / Overweight A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes 3 600 Change from Baseline in Hemoglobin A1c (HbA1c) Aug 2027 Aug 2027 NCT07668336 Diabetes Mellitus, Type 2 A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes 3 170 Change from Baseline in Hemoglobin A1c (HbA1c) Mar 2030 Mar 2030 NCT07613307 Diabetes Mellitus, Type 2 A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting 3 130 Change from Baseline in Hemoglobin A1C (HbA1c) May 2027 May 2027 Not for promotional use 41 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Select Trials – Orforglipron (cont.)
Page 42
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT05023980 Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL- 313) 3 309 To evaluate progression-free survival (PFS) of pirtobrutinib (Arm A) compared to bendamustine and rituximab (Arm B) Jul 2025 Oct 2027 NCT05254743 Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN-CLL- 314) 3 737 Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (Cri), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 1 Oct 2027 Jan 2028 NCT04666038 Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321) 3 238 Progression-Free Survival (PFS) Assessed by Independent Review Committee (IRC) Aug 2023 May 2027 NCT04965493 Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322) 3 600 To evaluate progression-free survival (PFS) of pirtobrutinib plus venetoclax and rituximab (Arm A) compared to venetoclax and rituximab (Arm B) Oct 2026 Oct 2027 Not for promotional use 42 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Select Trials – Pirtobrutinib
Page 43
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT04662255 Mantle Cell Lymphoma Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN-MCL-321) 3 500 To compare progression-free survival (PFS) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL) Jan 2027 Apr 2028 NCT06721013 Immune Thrombocytope nia A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia 1/2 68 Ph. 1 - Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration May 2028 May 2029 Not for promotional use 43 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Select Trials – Pirtobrutinib (cont.)
Page 44
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT06653153 Alzheimer's Disease A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3) 3 1400 Time to Clinically Meaningful Progression as Measured by Clinical Dementia Rate Scale (CDR) Apr 2029 Oct 2030 Not for promotional use 44 1 CT.gov update in progress * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Select Trials – Remternetug
Page 45
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT06662383 Obesity A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5) 3 800 Percent Change from Baseline in Body Weight Nov 2026 Dec 2026 NCT06859268 Obesity A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity (TRIUMPH-6) 3 643 Percent Change from Baseline in Body Weight Apr 2028 Apr 2028 NCT07035093 Obesity / Chronic Low Back Pain A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain (TRIUMPH-7) 3 586 Percent Change from Baseline in Body Weight | Change from Baseline in Pain Intensity Per Numeric Rating Scale Sep 2027 Sep 2027 NCT07232719 Obesity / Overweight A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8) 3 250 Percent Change from Baseline in Body Weight Jul 2027 Jul 2027 NCT07357415 Obesity / Overweight A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (TRIUMPH-9) 3 600 Percent Change from Baseline in Body Weight Oct 2028 Nov 2028 NCT06383390 Atherosclerotic Cardiovascular Disease / CKD The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) 3 10000 Time to First Occurrence of Composite Endpoints Feb 2029 Feb 2029 NCT06260722 Type 2 Diabetes Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) 3 1250 Change from Baseline in HbA1c Aug 2026 Jan 2027 NCT06297603 Type 2 Diabetes Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) 3 320 Change from Baseline in HbA1c Oct 2026 Nov 2026 Not for promotional use 45 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Select Trials – Retatrutide
Page 46
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT04194944 Non-Small Cell Lung Cancer A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non- Small Cell Lung Cancer (LIBRETTO-431) 3 261 Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) May 2023 Jun 2030 NCT04819100 Non-Small Cell Lung Cancer A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432) 3 152 Event-Free Survival (EFS), EFS by Investigator Assessment in the Primary Analysis Population Jan 2026 May 2028 NCT04211337 Medullary Thyroid Cancer A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO- 531) 3 291 Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) May 2023 Nov 2027 NCT03157128 Non-Small Cell Lung Cancer / Medullary Thyroid Cancer A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) 1/2 857 Phase 1: MTD, Incidence rate and category of dose limiting toxicities (DLTs) during the first 28-day cycle of LOXO-292 (selpercatinib) treatment Feb 2025 Feb 2027 NCT03899792 Solid Tumors / CNS Tumors (Pediatric) A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors (LIBRETTO-121) 1/2 36 Number of Participants With Dose-Limiting Toxicities (DLTs) Nov 2024 May 2029 Not for promotional use 46 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Select Trials – Selpercatinib
Page 47
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT07213804 Ovarian Neoplasms A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer (FRAmework-01) 3 1630 Progression-free Survival (PFS), per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator Nov 2028 Aug 2031 Not for promotional use 47 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Select Trials – Sofetabart Mipitecan
Page 48
2026 Q2 Earnings Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion NCT05556512 Obesity / Overweight A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO) 3 15374 Time to First Occurrence of a Major Adverse Cardiovascular Event (MACE) or All-Cause Death Oct 2027 Oct 2027 NCT06914895 Type 1 Diabetes / Obesity A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-1) 3 905 Change from Baseline in HbA1c Nov 2026 Dec 2026 NCT06962280 Type 1 Diabetes / Obesity A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-2) 3 465 Change from Baseline in HbA1c Nov 2026 Jul 2027 NCT06439277 Obesity (Adolescents) A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT- ADOLESCENTS-2) 3 300 Percent Change from Baseline in Body Mass Index (BMI) Oct 2027 Dec 2030 NCT06075667 Obesity / Overweight (Adolescents) A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities 3 160 Percent Change from Baseline in Body Mass Index (BMI) Jun 2026 Jul 2029 NCT07165028 MASLD A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) 3 4500 Time to First Occurrence of Any Component of the Composite Endpoint for Major Adverse Liver Outcomes Aug 2030 Aug 2032 NCT05536804 Obesity / Chronic Kidney Disease A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TREASURE-CKD) 2 140 Change from Baseline in Kidney Oxygenation in Participants With or Without T2D Sep 2026 Oct 2026 NCT06037252 Type 2 Diabetes / Obesity A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity 2 414 Percent Change From Baseline in Body Weight Jan 2026 Oct 2026 Not for promotional use 48 Source: clinicaltrials.gov, July 30, 2026 Select Trials – Tirzepatide * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes
Page 49
2026 Q2 Earnings Molecule Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion Bimagrumab NCT06643728 Obesity / Overweight A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight 2 252 Percent Change from Baseline in Body Weight Jan 2026 Jan 2027 GS Insulin Receptor Agonist NCT07215312 Type 2 Diabetes A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin 2 100 Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis) Nov 2026 Dec 2026 Macupatide NCT07215559 Obesity / Overweight / T2D A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes 2 200 Percent Change from Baseline in Body Weight Mar 2027 May 2027 Macupatide NCT07589608 Overweight / Obesity A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight 2 400 Percent Change from Baseline in Body Weight Sep 2027 Feb 2028 Not for promotional use 49 Source: clinicaltrials.gov, July 30, 2026 Early Phase Cardiometabolic Health * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes
Page 50
2026 Q2 Earnings Molecule Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion Nisotirostide NCT06897475 Type 2 Diabetes A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide 2 240 Change from Baseline in HbA1c Dec 2026 Jan 2027 NLRP3 INH II NCT06836232 Recurrent Pericarditis An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis 2 50 Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to study treatment discontinuation (or Safety and tolerability of VTX2735) Oct 2027 Oct 2027 Solbinsiran NCT07269210 Severe Hypertriglycerid emia A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia 2 60 Change from Baseline in Triglycerides Mar 2027 Aug 2027 Not for promotional use 50 Source: clinicaltrials.gov, July 30, 2026 Early Phase Cardiometabolic Health, continued * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes
Page 51
2026 Q2 Earnings Molecule Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion Eltrekibart NCT06046729 Hidradenitis Suppurativa A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa 2 352 Percentage of Participant Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) Sep 2025 Aug 2026 Zotemtegrast NCT07415044 Ulcerative Colitis LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3) 2 1431 Percentage of Participants Who Achieve Clinical Remission with Modified Mayo Score (mMS) Jun 2030 Jul 2031 Zotemtegrast NCT06226883 Crohn's Disease A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease 2 385 Proportion of participants with endoscopic response at Week 14 determined using the Simple Endoscopic Score-CD (SES-CD) Sep 2028 Jun 2030 Zotemtegrast NCT05611671 Ulcerative Colitis A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC (EMERALD-2) 2 280 Percentage of participants in clinical remission at Week 12 as determined using the Modified Mayo Clinic Score (mMCS) Nov 2024 Aug 2026 XCL1/2 antibody NCT07533019 Non-Segmental Vitiligo A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo 2 66 Percentage of Participants Achieving Facial Vitiligo Area Scoring Index (F-VASI) 75 May 2027 Sep 2027 Not for promotional use 51 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Early Phase Immunology
Page 52
2026 Q2 Earnings Molecule Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion Amezosvatein NCT05304351 Herpes Zoster Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older 2 1516 Occurrence of solicited local and systemic signs and symptoms Jun 2026 Mar 2032 Not for promotional use 52 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Early Phase Infectious Disease
Page 53
2026 Q2 Earnings Molecule Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion Cleminorexton NCT07598708 Central Disorders of Hypersomnolence A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence 2/3 222 Change from baseline in mean sleep latency (average of the first 4 trials) on the Maintenance of Wakefulness Test (MWT) Sep 2027 Dec 2027 AT2R Antagonist NCT07285018 Diabetic Peripheral Neuropathic Pain A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain 2 150 Change from Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) Jul 2027 Jul 2027 NAV 1.8 INH NCT07511816 Pain Following Third Molar Removal A Study of LY4515100 in Participants With Pain Following Third Molar Removal 2 212 Change from Baseline in Self-Reported Pain Intensity Nov 2026 Dec 2026 Anti-VEGF Gene Therapy NCT06517888 Vestibular Schwannoma Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma 1/2 27 AEs with Relationship to the Investigational Medicinal Product and/or to the Administration Procedure (including the Delivery Device) Aug 2029 Aug 2029 GBA1 Gene Therapy NCT04127578 Parkinson's Disease (GBA1 Mutation) Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL) 1/2 32 Cumulative number of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Dec 2030 Dec 2030 OTOF Gene Therapy NCT05821959 Sensorineural Hearing Loss, Bilateral Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss 1/2 22 Frequency of Adverse Events Oct 2028 Oct 2028 Not for promotional use 53 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Early Phase Neuroscience
Page 54
2026 Q2 Earnings Molecule Study Indication* Title Phase Patients Primary Outcome** Primary Completion Completion GIPR Agonist LA NCT07169851 Chemotherapy- Induced Nausea / Vomiting A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer 2 204 Proportion of Participants With Complete Response (CR) in the Delayed Phase of CINV Dec 2026 Feb 2027 Tersolisib NCT05768139 Breast Cancer First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (PIKALO-1) 1/2 880 Number of participants who experience at least 1 Dose Limiting Toxicity (DLT) Jul 2030 Jul 2030 Not for promotional use 54 * Molecule may have multiple indications. ** Trial may have additional primary and other secondary outcomes Source: clinicaltrials.gov, July 30, 2026 Early Phase Oncology
Page 55
2026 Q2 Earnings Not for promotional use 55 Trademarks All trademarks and trade names referred to in this earnings update are the property of the company, or, to the extent tradema rks or trade names belonging to other companies are referenced in this earnings update, the property of their respective owners. Solely for convenience, the trademarks and trade na mes in this earnings update are referred to without the ® and symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their re sp ective owners will not assert, to the fullest extent under applicable law, the company’s or their rights thereto. We do not intend the use or display of other comp ani es’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.